Athletic Endurance Protocol

Overview

Endurance performance is fundamentally a mitochondrial and metabolic conversation. The athlete who can oxidize fat efficiently, buffer lactate well, and recover between sessions without breakdown will outperform the one relying on high-carbohydrate output alone. Training is the primary stimulus; nutrition, sleep, and periodization are the dominant recovery levers. Peptides occupy a small but meaningful niche at the margin.

This protocol is aimed at the serious recreational or masters endurance athlete — runners, cyclists, triathletes, rowers — who has a well-established training base and wants to support mitochondrial biogenesis and tissue resilience. MOTS-c is the central metabolic tool; BPC-157 is used prophylactically and responsively to manage the repetitive soft-tissue stress endurance volume produces.

Compounds Involved

MOTS-c

MOTS-c directly addresses the central adaptation endurance athletes chase — mitochondrial density and metabolic flexibility. It is layered on training rather than substituted for it; the combined effect is greater than either alone.

BPC-157

High-volume endurance work produces chronic low-grade soft-tissue stress — Achilles, patellar tendon, plantar fascia, hip flexors. BPC-157 is used prophylactically during high-volume blocks or responsively at the first sign of tendinopathy.

AOD-9604 (Optional)

AOD-9604 is included as an optional tool for athletes carrying extra body composition into endurance work. It is mild compared to full GH analogs and is generally well tolerated.

Protocol Structure

Phase 1 — Base Building (6–12 weeks)

• Training — Zone 2 aerobic volume 5–7 hours/week, 1 weekly strength session, 1 tempo/threshold session
• MOTS-c 5 mg subcutaneous 2x/week (e.g., Monday and Thursday), ideally pre-Zone 2 session
• BPC-157 250 mcg/day subcutaneous, continuous during heaviest volume weeks
• Beta-alanine 4 g/day split into 2 doses
• Nutrition — 1.4–1.8 g/kg protein, adequate carbohydrate periodization around sessions

Phase 2 — Build / Intensity (4–8 weeks)

• Training — reduce total volume 10–15%, add a second threshold or VO2max session
• MOTS-c 10 mg 2x/week during peak weeks
• BPC-157 maintained at 250 mcg/day; can increase to 500 mcg during any acute niggle
• Consider AOD-9604 300 mcg fasted pre-morning session if body composition is a limiter
• Prioritize sleep (8+ hours) and carbohydrate availability around hard sessions

Phase 3 — Taper and Compete

• Cut training volume 30–50% in the final 2 weeks
• Discontinue MOTS-c and AOD-9604 at least 2 weeks before any tested competition — see Pre-Competition Protocol
• BPC-157 should likewise be discontinued per event anti-doping rules
• Emphasize sleep, familiar nutrition, and dress rehearsal of race-day logistics

Phase 4 — Post-Season Recovery

• 2–3 weeks of unstructured, low-volume aerobic activity
• Optional BPC-157 250 mcg/day to close out lingering soft-tissue issues
• Run a 4-week complete pharmacologic off-cycle before beginning the next base phase

Important Considerations

• All peptides referenced are prohibited under WADA and most other anti-doping authorities. Tested athletes must not use this protocol in- or out-of-competition (see Pre-Competition Protocol for detail).
• Endurance adaptation is dominated by training stimulus; peptides provide perhaps 3–5% at the margin. Do not expect transformative performance gains.
• MOTS-c dosing pre-Zone 2 is anecdotal; research timing is still being explored. Consistency matters more than exact timing.
• BPC-157 is not a replacement for proper loading progression. Increasing mileage by 20% per week while "covering" with peptides is how overuse injuries develop.
• Monitor basic labs every 3–6 months: CBC, metabolic panel, iron panel, vitamin D, and in masters athletes, lipid panel and HbA1c.
• Hydration and electrolyte strategy is often the rate-limiting factor in endurance performance, not pharmacology.
• Heart arrhythmias, unexplained fatigue, or chest symptoms warrant cardiology evaluation in any endurance athlete, particularly masters athletes.

Disclaimer

This content is for educational and informational purposes only. It is not medical advice and does not constitute a recommendation to use any peptide. MOTS-c, BPC-157, and AOD-9604 are not FDA-approved for human use and are prohibited under most anti-doping frameworks in and out of competition. Consult a qualified sports medicine clinician before beginning any peptide or training protocol, particularly if you have cardiovascular, metabolic, or musculoskeletal conditions. Pepperpedia does not endorse the acquisition or use of unapproved substances.